Recently, a point mutation in the coagulation Factor V gene (G to A in position 1691) has been identified which makes the mutant Factor V (called Factor V Leiden) resistant to activated protein C. This defect is a well established genetic risk factor in venous thrombosis. Because of the high prevalence of Factor V Leiden in normal population (2-7%), it would be reasonable to perform a rapid and simple method for screening the genetic abnormality in population at risk.
We have developed a simple, reproducible, rapid and cheap procedure that, using PCR and SSCP, allows the identification of the mutation responsible for Factor V Leiden. Specificity of this method has been tested in 319 samples: 304 normal, 14 heterozygous and 1 homozygous for Factor V Leiden. This assay allows non-isotopic Factor V Leiden identification by using frozen whole blood in 3 h. All these features make this test adequate for routine screening of this mutation in a large number of samples.
References
1
Dahlbäck B,
Carlsson M,
Svensson PJ.
Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
5
Beauchamp NJ,
Daly ME,
Hampton KK,
Cooper PC,
Preston FE,
Peake IR.
High prevalence of a mutation in the factor V gene within the U.K. population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-222
7
Dahlbäck B.
Resistance to activated protein C, the Arg 506 to Gin in the factor V gene, and venous thrombosis. Functional test and DNA-based assays, pros and cons. Thromb Haemost 1995; 73: 739-742
9
Leroy-Matheron C,
Levent M,
Pignon J-M,
Mendoca C,
Gouault-Heilmann M.
The 1691 G - A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemost 1996; 75: 4-10
10
Bertina RM,
Koeleman BPC,
Koster T,
Rosendaal FR,
Dirven RJ,
de Ronde H,
van der Velden PA,
Reitsman PH.
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
11
Gandrille S,
Alhenc-Gelas M,
Aiach M.
A rapid screening method for the factor V Arg506 - Gin mutation. Blood Coagulation and Fibrinol 1995; 6: 245-248
12
van de Locht LTF,
Kuypers AWHM,
Verbruggen BW,
Linssen PCM,
Novakova IRO,
Mensink EJBM.
Semi-automated detection of the factor V mutation by allele specific amplification and capillary electrophoresis. Thromb Haemost 1995; 74: 1276-1279
13
Rabes JP,
Trossaert M,
Conard J,
Giraudet P,
Boileau C.
Single point mutation at Arg (506) of factor V associated with APC resistance and venous thromboembolism: improved detection by PCR-mediated site-directed mutagenesis. Thromb Haemost 1995; 74: 1379
14
Kirschbaum NE,
Foster PA.
The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thromb Haemost 1995; 74: 874-878
15
Orita M,
Iwahana H,
Kanazawa H,
Hayashi K,
Sekiya T.
Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2766-2770
16
Ridker PM,
Hennekens CH,
Lindpaintner K,
Stampfer MJ,
Eisenberg PR,
Miletich JP.
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917
21
Ainsworth PJ,
Surh LC,
Coulter-Mackie MB.
Diagnostic single strand conformational polymorphism (SSCP): a simplified non-radioisotopic method as applied to a Tay-Sachs B1 variant. Nucleic Acid Res 1991; 19: 405-406
23
Mohabeer AJ,
Hiti AL,
Martin WJ.
Non-radioactive single strand conformation polymorphism (SSCP) using the Pharmacia “Phastsystem”. Nucleic Acid Res 1991; 19: 3154
